[HTML][HTML] Dendritic cells based immunotherapy
N Shang, M Figini, J Shangguan, B Wang… - American journal of …, 2017 - ncbi.nlm.nih.gov
Dendritic cells (DCs) are the most potent antigen-presenting cells, and tumor antigen-loaded
DCs (DC-vaccines) can activate tumor-specific cytotoxic T lymphocytes (CTLs) in lymphatic …
DCs (DC-vaccines) can activate tumor-specific cytotoxic T lymphocytes (CTLs) in lymphatic …
Terminally modified RNA
T Chakraborty, S Bancel, SG Hoge, A Roy… - US Patent …, 2017 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49447811&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
49447811&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Delivery and formulation of engineered nucleic acids
A De Fougerolles, SM Elbashir - US Patent 9,533,047, 2017 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
46147671&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
46147671&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Engineered nucleic acids and methods of use thereof
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
45893552&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
45893552&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Modified polynucleotides encoding hepatitis A virus cellular receptor 2
S Bancel, T Chakraborty, A De Fougerolles… - US Patent …, 2017 - Google Patents
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
49235350&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
S Bancel, T Chakraborty, A De Fougerolles… - US Patent …, 2017 - Google Patents
2016-05-02 Assigned to MODERNA THERAPEUTICS, INC. reassignment MODERNA
THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR …
THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR …
[HTML][HTML] The basics of artificial antigen presenting cells in T cell-based cancer immunotherapies
LR Neal, SR Bailey, MM Wyatt, JS Bowers… - … research and therapy, 2017 - ncbi.nlm.nih.gov
Adoptive T cell transfer (ACT) can mediate objective responses in patients with advanced
malignancies. There have been major advances in this field, including the optimization of …
malignancies. There have been major advances in this field, including the optimization of …
Modified polynucleotides for the production of oncology-related proteins and peptides
S Bancel, T Chakraborty, A De Fougerolles… - US Patent …, 2017 - Google Patents
2016-03-17 Assigned to MODERNA THERAPEUTICS, INC. reassignment MODERNA
THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR …
THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR …
Accessory molecule and costimulation requirements for CD4 T cell response
M Croft, C Dubey - Critical Reviews™ in Immunology, 2017 - dl.begellhouse.com
ABSTRACT T cell activation is brought about by recognition of peptide/MHC complexes on
an antigen-presenting cell (APC) by the T cell receptor (TCR). However, in general this …
an antigen-presenting cell (APC) by the T cell receptor (TCR). However, in general this …
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
45893552&utm_source= google_patent&utm_medium= platform_link&utm_campaign …
45893552&utm_source= google_patent&utm_medium= platform_link&utm_campaign …